Last reviewed · How we verify

Wills Eye — Portfolio Competitive Intelligence Brief

Wills Eye pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Use of bromfenac 0.09% to reduce intravitreal injection pain Use of bromfenac 0.09% to reduce intravitreal injection pain marketed
Triesence Triesence marketed Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Wills Eye:

Cite this brief

Drug Landscape (2026). Wills Eye — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/wills-eye. Accessed 2026-05-13.

Related